Recently, a potential combinatorial therapeutic approach for MPN patients has been proposed, by targeting inflammation through reduction of NfκB activity using BET inhibition in combination with JAK inhibition (62). This evidence concerns the gene NFKB1 and myeloproliferative neoplasm.